LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06865885

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06865885
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06865885. Randomized; no masking; primary purpose treatment. Start 2025-04-02 (actual); primary completion 2028-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
Acronym
SOLVE-LDL-C
Condition
Drug Interactions
Condition
Primary Prevention
Condition
Cardiometabolic Syndrome
Condition
LDL-Cholersterol Lowering
Condition
Polypharmacy
Intervention (Drug)
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Lead sponsor
University of California, San Diego (class: other)
Collaborator
Novartis (class: industry)

Record details

Record id
cardio:ct-nct06865885
Content hash
cb2af4e86dd4741fca81d5c467e0f1ec14dacf635667591cf120573a5a00b08f